Quarter Comparison

SELLAS Life Sciences Group, Inc. logo
SELLAS Life Sciences Group, Inc.— Sankey Diagram

Quarterly mode · period ending 2024-03-31 · View 10-Q on SEC EDGAR

ComparingFY2024 (Q1+Q2+Q3+Q4) vs FY2023 (Q1+Q2+Q3+Q4)
Revenue
$79K
↓-56.6% -$103Kvs FY2023 (Q1+Q2+Q3+Q4)
Gross Profit
$79K
↓-56.6% -$103Kvs FY2023 (Q1+Q2+Q3+Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
Reconciled values per the quarterly mode pipeline. Compare against SEC EDGAR filings.
Line itemFY2024 (Q1+Q2+Q3+Q4)FY2023 (Q1+Q2+Q3+Q4)
Revenue$79K$182K
COGS$0$0
Gross Profit$79K$182K
R&D$22M$23M
SG&A$14M$14M
D&A$0$0
Other OpEx$0$0
Operating Income$0$0
Interest Exp.$0$0
Other Non-Op$0$0
Pretax Income$0$0
Tax$0$0
Net Income$0$0

QuarterCharts · SEC EDGAR data · SLS · Comparing FY2024 (Q1+Q2+Q3+Q4) vs FY2023 (Q1+Q2+Q3+Q4)